Pfizer Gains Anti-Inflammatory Compound Development Rights Through Incyte Deal
Under the agreement for CCR2 antagonists, Incyte will maintain rights to multiple sclerosis and a second undisclosed indication.
Under the agreement for CCR2 antagonists, Incyte will maintain rights to multiple sclerosis and a second undisclosed indication.